Log In
Print
BCIQ
Print
Print this Print this
 

Lestaurtinib (CEP-701) (formerly KT-5555)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionInhibitor of several tyrosine kinases including FMS-like tyrosine kinase 3 (FLT3) and janus kinase-2 (JAK-2)
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135) ; Janus kinase-2 (JAK-2)
Mechanism of ActionFMS-like tyrosine kinase 3 (FLT3) inhibitor; Janus kinase-2 (JAK-2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMyeloproliferative disorder
Indication DetailsTreat myelofibrosis; Treat myeloproliferative disorders (MPD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today